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Background: Rotaviruses are the leading cause of severe acute gastroenteritis in children aged <5 years worldwide.
A live attenuated human rotavirus vaccine, RIX4414 has been developed to reduce the global disease burden associated
with rotavirus gastroenteritis. Serum anti-rotavirus immunoglobulin A (IgA) antibody measured in unvaccinated infants
during clinical trials of RIX4414 reflects natural rotavirus exposure, and may inform the optimal timing for rotavirus
vaccination.
Methods: We reviewed phase II and III randomized, placebo-controlled clinical trials conducted by GlaxoSmithKline
Vaccines, Wavre, Belgium between 2000 and 2008 which used the commercial formulation of RIX4414 lyophilized
vaccine. We included trials for which demographic data and pre-dose-1 and post-last-dose anti-rotavirus IgA
antibody status were available from placebo recipients.
Results: Sixteen clinical trials met the inclusion criteria. The studies were conducted across Africa (N = 3), Asia
(N = 4), Latin America (N = 4), Europe (N = 4) and North America (N = 1). Overall, 46,398 infants were enrolled and
among these, 20,099 received placebo. The mean age at pre-dose-1 time point ranged from 6.4 − 12.2 weeks
while the mean age at post-last-dose time point ranged from 13.5 − 19.6 weeks. The anti-RV IgA seropositivity
rates at both time points were higher in less developed countries of Africa, Asia and Latin America (pre-dose-1:
2.1%-26.3%; post-last-dose: 6.3%-34.8%) when compared to more developed countries of Asia, Europe and North
America (pre-dose-1: 0%-9.4%; post-last-dose: 0%-21.3%), indicating that rotavirus infections occurred at a younger
age in these regions.
Conclusion: Exposure to rotavirus infection occurred early in life among infants in most geographical settings,
especially in developing countries. These data emphasize the importance of timely rotavirus vaccination within
the Expanded Program on Immunization schedule to maximize protection.
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Rotaviruses are a leading cause of severe acute gastro-
enteritis, resulting in approximately 453,000 annual deaths
among children less than five years of age [1] with over
85% of these deaths occurring in the less developed coun-
tries of Asia and Africa [1,2]. Children typically experience
multiple rotavirus infections during childhood, which may* Correspondence: htay.h.han@gsk.com
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unless otherwise stated.result in mild or asymptomatic infection to severe, life-
threatening illness [3]. The first rotavirus infection is gen-
erally the most severe with subsequent rotavirus infections
generally resulting in less severe disease outcomes because
of acquisition of protective immunity, the extent of which
varies by location [4,5].
Immunization of infants with oral, live attenuated
rotavirus vaccine that mimics natural infection, prior to
their first exposure to natural rotavirus infection is con-
sidered the best strategy to reduce the global disease
burden [3,4]. A live attenuated human rotavirus vaccine,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Belgium) is administered orally according to a two dose
schedule. The first dose can be administered as early as
6 weeks of age with a minimum of 4 weeks interval rec-
ommended between doses [6]. RIX4414 has undergone
an extensive worldwide evaluation program. More than
30 clinical studies have been conducted to evaluate its
safety, immunogenicity and efficacy, involving over 100,000
children in five continents. Such safety and efficacy studies
in Europe [7], Latin America [8] and Asia [9] have con-
firmed that the vaccine is safe [10], well-tolerated [11] and
efficacious (range: 80-96%) in preventing severe rotavirus
gastroenteritis in the first two years of life. RIX4414 is
now licensed in over 110 countries [12] and is included
in the national immunization programs of low income/
developing countries as well as in high income/developed
countries.
From a public health perspective, it is important to
identify the optimal age for the completion of rotavirus
vaccination to obtain maximum benefit. To achieve this,
we evaluated data obtained from placebo-controlled clin-
ical trials conducted by GSK Biologicals using RIX4414
across different regions of the world. From all these stud-
ies, data on anti-rotavirus immunoglobulin A (IgA) anti-
body levels at pre-dose-1 and post-last-dose time points in
the placebo recipients (of the total vaccinated cohort)
were examined. The data available from the clinical trials
reported in this review were used to assess the trend in ex-
posure and age at infection.
Methods
Clinical study reports of all randomized, double-blind and
placebo-controlled phase II and phase III trials conducted
between 2000 and 2008 using the commercial lyophilized
formulation of RIX4414 vaccine were reviewed. Only stud-
ies with available data on anti-rotavirus IgA antibody sero-
positivity status at pre-dose-1 and post-last-dose time
points for placebo recipients were included.
In all the included studies, each dose of the commer-
cial formulation of RIX4414 contained at least 106.0 me-
dian cell-culture infective doses (CCID50) of the vaccine
strain. The placebo contained the same constituents as
the active vaccine but without the virus component.
Both were reconstituted with liquid calcium carbonate-
based buffer before administration.
Blood samples were collected at pre-dose-1 and one to
two months post-last-dose of placebo to measure the
anti-rotavirus IgA antibody concentration using ELISA
(Laboratory of Dr R. Ward, Children’s Hospital Medical
Centre, Cincinnati, USA or at GlaxoSmithKline Laboratories,
Rixensart, Belgium). The assay cut-off for seropositivity
was set at 20 U/ml [13,14].
The demographic and serological data of the placebo
group of the total vaccinated cohort were included inthe analysis. The placebo group of the total vaccinated
cohort comprised infants who had received at least one
dose of placebo. Demography in terms of age range, gen-
der and race were tabulated per study. Anti-rotavirus
IgA seropositivity rates pre-dose-1 and one to two
months post-last-dose of placebo and the mean age with
standard deviation at the pre-dose-1 and post-last-dose
time points were tabulated per study.
In all the study centers, the protocols, amendments and
informed consent forms were reviewed and approved by
the respective ethics committees. These studies were per-
formed in accordance with the Good Clinical Practice
guidelines and Declaration of Helsinki where applicable.
Written informed consent was obtained from the parents/
guardians of participating infants before carrying out any
study-related procedures.
Results
Of the 27 clinical study reports reviewed, 16 studies met
the inclusion criteria (Table 1). Among the excluded
studies, five studies had formulation of the vaccine with
less than 106.0 CCID50 of vaccine strain, one study had
liquid formulation of RIX4414 vaccine, two studies did
not include placebo groups and for the remaining three
studies pre-dose-1 and/or post-last-dose anti-rotavirus
IgA antibody data were unavailable. The included studies
were conducted in Africa (N = 3), Asia (N = 4), Latin
America (N= 4), Europe (N= 4) and North America (N= 1).
Two studies (Rota-054 [11] and Rota-022 [15]) enrolled
pre-term babies and HIV-positive infants respectively.
A total of 46,398 infants were enrolled in these 16 stud-
ies, of which 20,099 infants had received at least one
dose of placebo.
The demographic characteristics of the infants in all
these studies are summarized in Table 2. The mean age
at pre-dose-1 time point ranged from 6.4 weeks to
12.2 weeks while the mean age at post-last-dose time
point ranged from 13.5 weeks to 19.6 weeks.
Africa: Two phase II and one phase III study were
conducted to evaluate the safety, efficacy and immuno-
genicity of RIX4414 (Rota-013, Rota-022 and Rota-037)
[15,16]. At approximately 6 weeks of age (pre-dose-1
time point), the anti-rotavirus seropositivity rates in the
placebo groups ranged from 4.3% (Rota-013) to 13.0%
(Rota-022) (Table 3 and Figure 1). In the Rota-037 study
conducted in South Africa and Malawi, the country-
specific pre-dose-1 seropositivity rates were 12.2% (11/90)
and 10.4% (7/67), respectively. In both Rota-013 and Rota-
022, conducted in Africa, at the post-last-dose time point
(15–16 weeks of age) the seropositivity rates increased to
a maximum of 29.4% (Table 3). In Rota-037, although
the overall anti-rotavirus seropositivity rate after the
completion of the last placebo dose (8–21 weeks of
age) was 25.2%, an apparent difference was observed in
Table 1 Summary of the studies included




Number of infants in
the placebo group
Reference
Africa South Africa 444563/013 (Rota-013) Phase II, randomized, double-blind,
placebo-controlled
2 or 3 doses; 0,1,2 month 475 96 -
South Africa 444563/022 (Rota-022) Phase II, randomized, double-blind,
placebo-controlled
3 doses; 0,1,2 month 100 50 [15]
South Africa, Malawi 102248 (Rota-037) Phase III, randomized, double-blind,
placebo-controlled
2 or 3 doses; 0,1,2 month 4939 1641 [16]
Asia Korea 103478 (Rota-041) Phase II, randomized, double-blind,
placebo-controlled
2 doses; 0,2 month 161 52 [17]
India 103792 (Rota-044) Phase IIIb, randomized, double-blind,
placebo-controlled
2 doses; 0,1 month 363 181 [18]
Bangladesh 103992 (Rota-045) Phase II, randomized, double-blind,
placebo-controlled
2 doses; 0,1 month 300 98 [19]
Singapore, Hong Kong, Taiwan 444563/028/029/030
(Rota-028, −029, −030)
Phase III, randomized, double-blind,
placebo-controlled
2 doses; 0,1 or 2 month 10,708 5349 [9]
Latin
America
Brazil, Mexico and Venezuela 444563/006 (Rota 006) Phase IIb, randomized, double-blind and
placebo-controlled trial
2 or 3 doses; 0,2 or
0,2,4 month schedule
2155 537 [20]




444563/023 (Rota 023) Phase III, randomized, double-blind,
placebo-controlled
2 doses; 0,1-2 month 20,169 10,010 [21]
Mexico, Colombia, Peru 444563/033 (Rota-033) Phase II, randomized, double-blind,
placebo-controlled
2 doses; 0,2 month 854 124 -
Dominican Republic 106260 (Rota-052) Phase IIIb, randomized, double-blind,
placebo-controlled
2 doses; 0,2 month
schedule
200 100 [22]
Europe Finland 444563/003* (Rota-003) Phase II, randomized, double-blind,
placebo-controlled
2 doses; 0,2 month
schedule
192 16 [23]
Finland 104480 (Rota-048) Phase II, randomized, double-blind,
placebo-controlled
2 doses; 0,1 month 250 50 [12]
Finland, Czech Republic, France,
Germany, Italy, Spain
102247 (Rota-036) Phase IIIb, randomized, double-blind,
placebo-controlled
2 doses; 0,1-2 month
schedule
3994 1348 [7]
France, Portugal, Poland and Spain 106481 (Rota-054) Phase IIIb, randomized, double-blind,
placebo-controlled





United States and Canada 444563/005** (Rota 005) Phase II, randomized, double-blind,
placebo-controlled
2 doses; 0,2 month
schedule
529 108 [24]
*= Rota-003 was a dose escalation study with vaccines containing 105.3, 105.6 and 106.6 CCID50 of RIX4414 strain. Here were are presenting the results of the placebo group whose corresponding vaccine contained 10
6.6
CCID50 of RIX4414 strain.
**= Rota-005 used vaccines containing 105.6 and 106.8 CCID50 of RIX4414 strain. Here were are presenting the results of the placebo group whose corresponding vaccine contained 10


















Table 2 Demographic characteristics of the placebo group (of the Total vaccinated cohort)
Region Study number Age range of infants
enrolled at the time
of the first placebo
dose (weeks)
Gender (%) Majority race
Male Female
Africa 444563/013 (Rota-013) 5–10 53.1 46.9 African
444563/022 (Rota-022) 5-10 50.0 50.0 African
102248 (Rota-037) 2–11 51.2 48.8 African heritage/African
American
Asia 103478 (Rota-041) 7–12 46.2 53.8 Korean
103792 (Rota-044) 8–10 54.7 45.3 Indian
103992 (Rota-045) 12–15 45.8 54.2 Bangladeshi
444563 (Rota-028, −029, −030) 5 − 20 50.9 49.1 Chinese
Latin America 444563/006 (Rota 006) 6–12 50.3 49.7 Mestizo, Mestiza or Mixed
444563/023 (Rota 023) 2–13 51.7 48.3 Hispanic
444563/033 (Rota-033) 6–12 55.6 44.4 Hispanic
106260 (Rota-052) 6 − 13 51.0 49.0 American Hispanic or Latino
Europe 444563/003 (Rota 003) 6-12 62.5 37.5 White
104480 (Rota-048) 6–12 54.0 46.0 White - Caucasian/European
heritage
102247 (Rota-036) 5–18 51.3 48.7 White/Caucasian
106481 (Rota-054) 5–14 50.7 49.3 White - Caucasian/European
heritage
North America 444563/005 (Rota 005) 5-15 50.0 50.0 White/Caucasian
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and Malawi (38.0% [176/463]).
Asia: Four studies, one each in India (Rota-044),
Bangladesh (Rota-045), Korea (Rota-041) and a com-
bined study in Singapore, Hong Kong and Taiwan
(Rota-028, −029, −030) evaluated the safety, efficacy
and immunogenicity of the RIX4414 vaccine [9,18,19].
In this region, in the less developed countries, a max-
imum seropositivity rate of 26% was observed at pre-
dose-1 time point (approximately 9–12 weeks of age) in
India (Table 3 and Figure 1). The seropositivity rate
rose to a maximum of 35% at approximately 18 weeks
of age in Bangladesh (Table 3). In the developed coun-
tries, the seropositivity rates at pre-dose-1 and post-
last-dose time points were 0.7% and 1.5%, respectively
(Figure 1).
Latin America: In the immunogenicity and safety
studies conducted in Latin America (Rota-006, Rota-023,
Rota-033 and Rota-052) [20-22] the anti-rotavirus IgA
antibody seropositivity rates were close to a maximum of
9% (~8 weeks of age) at pre-dose-1 and 30% (~16 weeks
of age) at post-last-dose time points (Table 3). The post-
last-dose seropositivity rates were very similar to that seen
in Asia.
Europe: In Rota-003, Rota-048 [12], Rota-036 [25] and
Rota-054 [11], the pre-dose-1 anti-rotavirus seropositiv-
ity rates ranged from 0% to 9% (9–11 weeks of age).During the post-last-dose time point (16–20 weeks of
age), the seropositivity rates rose to a maximum of 21%
(Table 3 and Figure 1).
North America: In a phase II study conducted in
United States and Canada (Rota-005), none of the in-
fants were seropositive at the pre-dose-1 time point
(~9 weeks of age). The seropositivity rate rose to 9.3% at
post-last-dose time point (Table 4).
Discussion
Assessment of anti-rotavirus IgA seropositivity rate in
the placebo groups at pre-dose-1 and post-last-dose time
points in 16 studies across five geographical regions has
provided information on the approximate age at which
children are naturally infected by rotaviruses.
Although, epidemiological studies from different regions
have shown that the incidence of rotavirus infection is
highest in children aged 6–23 months, it is recognized
that rotavirus infection may occur in neonates and chil-
dren aged less than 2 months [26,27]. A study conducted
in 11 Latin American countries indicated that up to 11%
of rotavirus gastroenteritis (RV GE) cases were observed
in children younger than 3 months [28]. The REVEAL
study conducted across seven European countries showed
that the percentage of RV GE in the 0–2 months age
group ranged from 0.8% in Sweden to 6.1% in France
[27,29]. An hospital-based study in Malawi demonstrated
Table 3 Age and seropositivity rates at pre-dose-1 and post-last-dose time points in the placebo groups (of the Total vaccinated cohort)


















Africa South Africa 444563/013 (Rota-013) 6.4 ± 1.07 4.3 (4/94) 15.0 ± 2.32 8 6.3 (5/80)
South Africa 444563/022 (Rota-022) 6.9 ± 1.02 13.0 (6/46) 14.9 ± 1.64 8 29.4 (10/34)
South Africa, Malawi 102248 (Rota-037) 6.4 ± 0.97 11.5 (18/157) 16.3 ± 1.51 4 25.2 (348/1380)
Asia Korea 103478 (Rota-041) 10.5 ± 0.92 23.1 (12/52) 19.4 ± 1.09 8 20.4 (10/49)
India 103792 (Rota-044) 8.6 ± 0.69 26.3 (45/171) 13.5 ± 1.12 4 26.2 (43/164)
Bangladesh 103992 (Rota-045) 12.2 ± 0.47 15.2 (14/92) 16.8 ± 0.52 4 34.8 (32/92)
Singapore, Hong Kong, Taiwan 444563 (Rota-028, −029, −030) 11.6 ± 2.37 0.7 (1/135) 17.8 ± 1.55 4–8 1.5 (2/132)
Latin America Brazil, Mexico and Venezuela 444563/006 (Rota 006) 8.6 ± 1.98 2.1 (11/528) NA* 8 13.2 (24/182)
Argentina, Brazil, Chile, Colombia,
Dominican Republic, Honduras,
Mexico, Nicaragua, Panama, Peru
and Venezuela
444563/023 (Rota 023) 8.4 ± 2.37 3.5 (15/432) 16.3 ± 3.77 4–8 15.1 (60/398)
Mexico, Colombia, Peru 444563/033 (Rota-033) 8.6 ± 2.20 3.3 (4/121) NA* 8 13.1 (14/107)
Dominican Republic 106260 (Rota-052) 8.2 ± 1.80 9.3 (9/97) 14.2 ± 1.83 6 30.2 (29/96)
Europe Finland 444563/003 (Rota 003) 7.6 ± 1.75 0.0 (0/16) NA* 4 0.0 (0/14)
Finland 104480 (Rota-048) 9.3 ± 2.04 0.0 (0/49) 14.4 ± 2.12 4 0.0 (0/48)
Finland, Czech Republic, France,
Germany, Italy, Spain
102247 (Rota-036) 11.4 ± 1.84 2.1 (10/479) 19.6 ± 2.74 12 9.5 (45/473)
France, Portugal, Poland and Spain 106481 (Rota-054) 8.5 ± 1.78 9.4 (9/96) 16.0 ± 2.95 4 21.3 (20/94)
North America United States and Canada 444563/005 (Rota 005) 8.6 ± 1.31 0.0 (0/95) NA* 8 9.3 (8/86)
SD = Standard deviation.
n = number of infants in placebo groups with anti-rotavirus IgA antibody concentration ≥20 U/ml.
N = number of infants in placebo groups with available results.
Note: In all the studies mentioned above, the assessment of seropositivity rates was performed on a subset of total number of enrolled infants.


















Figure 1 Age and seropositivity rates at pre-dose-1 time point in the placebo groups (of the Total vaccinated cohort). Numbers on top
of the bars indicate mean age in weeks with standard deviation at pre-dose-1 time point.
Table 4 Trial registration numbers
















North America Rota-005 (444563/005)/NCT00729001
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three months of age [30]. A previous report indicated that
rotavirus infections in neonates are mostly nosocomial
and typically asymptomatic [31].
In line with this, the present review also showed that
infants were at risk of becoming infected with rotavi-
ruses prior to RV vaccination, as demonstrated by the
presence of anti-rotavirus IgA seropositivity rate at pre-
dose-1 time point in most of the regions. At pre-dose-1
and post-last-dose time points, highest seropositivity
rates (26% and 34% at pre-dose-1 and post-last-dose)
were observed at a younger age in less developed coun-
tries of Asia followed by Africa and Latin America. The
maximum baseline seropositivity rate was 26% in India
(Rota-044), which is in line with previously published
data [5], indicating that natural rotavirus infections may
occur very early in life furthering the need for neonatal
immunization. However, the seropositivity rates observed
in high-income Asian countries (Rota-028, −029, −030) at
post-last-dose time point was not only lower (1.5%) than
that observed in other low-income Asian countries, but
was in fact lower than that observed in Europe and North
America. This suggests that socioeconomic conditions,
overcrowding, malnourishment, sanitation and personal
Cunliffe et al. BMC Pediatrics 2014, 14:295 Page 7 of 9
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veloped countries at high risk of exposure to rotavirus at a
younger age compared to children living in developed or
high-income countries [3,32]. Furthermore, the Asian
Rotavirus Surveillance Network data indicated that rota-
virus disease-associated hospitalizations occur more fre-
quently at a younger age in low income than in high
income countries [33].
In Africa the anti-rotavirus seropositivity rate after the
last placebo dose was greater in Malawi compared to
South Africa suggesting a higher exposure to wild-type
rotavirus in the first five months of life in Malawian than
of South African infants. This observation may partly be
explained by the different enrolment patterns employed
during the Phase III trial (Rota-037) in these countries.
In South Africa, enrolment was timed before the rota-
virus season while in Malawi, enrolment was done all
year-round and no clear seasonality was observed [16].
In addition, lack of seasonality itself may be one of the
reasons for increased rotavirus infection occurring at an
earlier age in tropical countries where children are ex-
posed to rotavirus all year-round [34,35]. Furthermore, a
previously conducted study in Venezuela reported that
the infection rate and severity of the disease increased in
environments with minimal seasonality [36].
Although the overall seropositivity rates at pre-dose-1
and post-last-dose were lowest in Europe, a wide dispar-
ity was observed between studies. In the Rota-054 study,
the seropositivity rates at both time points were similar
to that observed in Asia, Africa and Latin America. Such
a difference may be attributed to the premature condi-
tion of the study population, making the infants suscep-
tible to rotavirus disease at an earlier age [11].
There are some limitations to this review: firstly, the
enrolment age across all the included studies was differ-
ent. Therefore, it was not possible to estimate the actual
age at which infants were first infected with rotavirus
and the severity of possible clinical symptoms. Secondly,
the seropositivity data available for each study were in-
dependent in terms of age-limit at the time of dose-1
and during post-last-dose time point, hence the age
groups of infants were not uniform. Furthermore, the
lack of seropositivity observed at pre-dose-1 and post-
last-dose time points in the Rota-003 and −048 trials
could be partly due to the low number of subjects in
each trial (n = 16 and n = 50, respectively). Thirdly, since
all these studies were conducted under a clinical trial
setting with definite criteria for enrollment, the data
may not precisely reflect a real-life setting. Additionally,
there are some studies that have shown that maternal
IgA antibody move transplacentally at a slow rate
[37,38] and the presence of RV-specific IgA in infant
sera at a young age could be due to the presence of ma-
ternal antibodies. Finally, it has also been suggested inearly reports that maternal antibodies play a role in
modulating the immunogenicity and efficacy of rotavirus
vaccines [39]; therefore the timing of vaccination needs
to be carefully selected. However, studies have also dem-
onstrated the administering the first dose of the rota-
virus vaccine in the neonatal period proves efficacious
and affords protection early on in life [40].
Conclusion
Exposure to rotavirus infection is common in the first
six months of life and varies by geographic region with
infants in some less developed settings having higher
rates of early RV infection as compared to that of infants
in developed settings. These observations reinforce the
need for completion of rotavirus vaccination in a timely
fashion when delivered through childhood immunization
programs.
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